Nuvation Bio Completes $250M Convertible Note Offering at 35% Premium, Repays $58.5M Debt
NUVB has more than doubled off its 52-week low of $1.865 on elevated volume (2.7× avg).
Summary
Nuvation Bio completed an upsized $250 million convertible senior note offering at a 35% conversion premium, using a portion of the proceeds to repay $58.5 million in existing debt and the remainder for general corporate purposes.
Key Events · Financing and Capital Events · NUVB
-
Completed Convertible Note Offering
Nuvation Bio completed an upsized $250 million offering of 0.75% Convertible Senior Notes due 2032. This follows the proposed offering announced on June 25, 2026, and the pricing finalized on June 26, 2026.
-
Premium Pricing & Dilution Mitigation
The notes feature an initial conversion price of approximately $7.84 per share, representing a 35% premium over the Class A common stock's last reported sale price of $5.81 on June 25, 2026. Capped call transactions were also executed to reduce potential stock dilution and/or offset cash payments upon conversion, with a cap price representing an 80% premium.
-
Debt Repayment
Approximately $58.5 million of existing debt under a Credit Agreement and Guaranty (Loan Agreement) was fully repaid using a portion of the offering proceeds, and the Loan Agreement was terminated.
-
Enhanced Financial Flexibility
The net proceeds from the offering, after deducting underwriting discounts, commissions, and capped call costs, are approximately $241.2 million. The remaining funds will be used for general corporate purposes, including working capital and operating expenses.
Analysis · NUVB · Life Sciences
Nuvation Bio Inc. has successfully completed its upsized $250 million offering of 0.75% Convertible Senior Notes due 2032. This capital raise is substantial, representing approximately 12.6% of the company's current market capitalization. The notes were priced at a significant 35% conversion premium to the stock's June 25th closing price, indicating strong institutional confidence in the company's future valuation. Furthermore, the company entered into capped call transactions, designed to mitigate potential dilution up to an 80% premium. A key use of the net proceeds was the full repayment of approximately $58.5 million in existing debt, strengthening the balance sheet and reducing financial obligations. The remaining funds will be allocated to general corporate purposes, including working capital and operating expenses, providing a solid financial runway.
At the time of this filing, NUVB was trading at $5.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $1.87 to $9.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.